Research Applications of PT-141 Peptide
Bremelanotide PT-141 is a cyclic heptapeptide derived from melanocortin-stimulating hormone that activates MC1R and MC4R melanocortin receptors in laboratory studies. Originally designated as PT-141 during development, this peptide demonstrates selective receptor binding patterns in peripheral nervous system research models. Scientists examine bremelanotide for its unique mechanism of action through melanocortin pathways, distinguishing it from vascular-targeting compounds in comparative studies. Research applications focus on receptor pharmacology and signal transduction mechanisms at Stroid UK Shop laboratory facilities.
Peptide Mechanism and Laboratory Studies
Laboratory investigations evaluate bremelanotide’s selective agonist activity at melanocortin receptor subtypes, particularly MC1R and MC4R isoforms. Research demonstrates rapid absorption characteristics in animal models, with bioavailability studies showing subcutaneous administration protocols in preclinical evaluations. Scientists study the cyclic heptapeptide structure for stability analysis and receptor binding kinetics compared to linear peptide analogues. The compound’s mechanism involves hypothalamic-neural pathway activation through melanocortin receptor systems, making it valuable for PT-141 research applications in neuropharmacology studies.
Euro-Pharmacies Laboratory Specifications
| Parameter | Specification |
|---|---|
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1025.16 g/mol |
| CAS Registry | 189691-06-3 |
| Peptide Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Storage Temperature | -20°C lyophilised, 2-8°C reconstituted |
| Stability Period | Use within 30 days when reconstituted |
Research facilities investigating melanocortin pharmacology often compare bremelanotide studies with other research compounds for receptor selectivity analysis. Advanced peptide research protocols require precise handling procedures and appropriate storage conditions.
Laboratory Research Compliance
This PT-141 bremelanotide peptide is supplied exclusively for in-vitro laboratory research by qualified researchers. Not approved for human consumption, therapeutic use, or clinical applications. Researchers must follow institutional guidelines for peptide handling and disposal. Laboratory studies should reference published pharmacological data and maintain proper documentation.
